enVVeno Medical Corp Files 8-K for Bylaws and Financials

TL;DR

enVVeno Medical Corp updated its bylaws and filed financials on 11/17/25.

AI Summary

On November 17, 2025, enVVeno Medical Corporation filed an 8-K report detailing amendments to its Articles of Incorporation and Bylaws. The filing also included financial statements and exhibits, with the report being filed as of November 20, 2025. The company, formerly known as Hancock Jaffe Laboratories, Inc., is based in Irvine, California.

Why It Matters

This filing indicates corporate governance updates and the submission of financial information, which are crucial for investors to assess the company's operational and legal standing.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediately alarming information.

Key Players & Entities

• enVVeno Medical Corporation (company) — Registrant
• Hancock Jaffe Laboratories, Inc. (company) — Former company name
• November 17, 2025 (date) — Date of earliest event reported
• November 20, 2025 (date) — Date filed
• Irvine, California (location) — Company address

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share NVNO The NASDAQ Stock Mar

Filing Documents

• form8-k.htm (8-K) — 36KB
• ex3-1.htm (EX-3.1) — 91KB
• 0001493152-25-024494.txt ( ) — 309KB
• nvno-20251117.xsd (EX-101.SCH) — 3KB
• nvno-20251117_lab.xml (EX-101.LAB) — 33KB
• nvno-20251117_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 enVVeno Medical Corporation (Exact name of registrant as specified in its charter) Delaware 001-38325 33-0936180 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 70 Doppler Irvine , California 92618 (Address of principal executive offices) (Zip Code) (949) 261-2900 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.00001 per share NVNO The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 17, 2025, the Board of Directors of enVVeno Medical Corporation ("we," "us," "our," or the "Company") approved an amendment to the Company's Amended and Restated Bylaws. The amendment revises Section 1.5 to modify the quorum requirement for meetings of stockholders. As amended, Section 1.5 provides that, except as otherwise required by applicable law, the certificate of incorporation or the bylaws, the presence in person or by proxy of holders of thirty-three and one-third percent in voting power of the outstanding shares entitled to vote at the meeting shall constitute a quorum. The amendment to Section 1.5 became effective immediately upon approval by the Board. Item 9.01 Financial Statements and Exhibits. Set forth below is a list of Exhibits included as part of this Current Report: Exhibit No. Description 3.1 Amended and Restated Bylaws of enVVeno Medical Corporation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVVENO MEDICAL CORPORATION Dated: November 20, 2025 /s/ Robert A. Berman Robert A. Berman Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR